References:
1. Ball EM, Bell AL. Lupus arthritis–do we have a clinically useful
classification? Rheumatology (Oxford) 2012; 51:771-9.
2. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al.
The 1982 revised criteria for the classification of systemic lupus
erythematosus. Arthritis Rheum 1982; 25:1271-7.
3. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et
al. Derivation and validation of the Systemic Lupus International
Collaborating Clinics classification criteria for systemic lupus
erythematosus. Arthritis Rheum 2012; 64:2677-86.
4. Zayat AS, Mahmoud K, Md Yusof MY, Mukherjee S, D’Agostino MA, Hensor
EMA, et al. Defining inflammatory musculoskeletal manifestations in
systemic lupus erythematosus. Rheumatology (Oxford) 2019; 58:304-12.
5. Tani C, D’Aniello D, Possemato N, Delle Sedie A, Caramella D,
Bombardieri S, et al. MRI pattern of arthritis in systemic lupus
erythematosus: a comparative study with rheumatoid arthritis and healthy
subjects. Skeletal Radiol 2015; 44:261-6.
6. Ceccarelli F, Perricone C, Cipriano E, Massaro L, Natalucci F,
Capalbo G, et al. Joint involvement in systemic lupus erythematosus:
From pathogenesis to clinical assessment. Semin Arthritis Rheum 2017;
47:53-64.
7. Goldenberg DL, Cohen AS. Synovial membrane histopathology in the
differential diagnosis of rheumatoid arthritis, gout, pseudogout,
systemic lupus erythematosus, infectious arthritis and degenerative
joint disease. Medicine (Baltimore) 1978; 57:239-52.
8. Schumacher HR, Jr., Howe HS. Synovial fluid cells in systemic lupus
erythematosus: light and electron microscopic studies. Lupus 1995;
4:353-64.
9. Labowitz R, Schumacher HR, Jr. Articular manifestations of systemic
lupus erythematosus. Ann Intern Med 1971; 74:911-21.
10. Nzeusseu Toukap A, Galant C, Theate I, Maudoux AL, Lories RJ,
Houssiau FA, et al. Identification of distinct gene expression profiles
in the synovium of patients with systemic lupus erythematosus. Arthritis
Rheum 2007; 56:1579-88.
11. Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou
CT, et al. The Assessment of SpondyloArthritis International Society
classification criteria for peripheral spondyloarthritis and for
spondyloarthritis in general. Ann Rheum Dis 2011; 70:25-31.
12. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO,
3rd, et al. 2010 Rheumatoid arthritis classification criteria: an
American College of Rheumatology/European League Against Rheumatism
collaborative initiative. Arthritis Rheum 2010; 62:2569-81.
13. Schinnerling K, Aguillon JC, Catalan D, Soto L. The role of
interleukin-6 signalling and its therapeutic blockage in skewing the T
cell balance in rheumatoid arthritis. Clin Exp Immunol 2017; 189:12-20.
14. Eilertsen GO, Nikolaisen C, Becker-Merok A, Nossent JC.
Interleukin-6 promotes arthritis and joint deformation in patients with
systemic lupus erythematosus. Lupus 2011; 20:607-13.
15. Ball EM, Gibson DS, Bell AL, Rooney MR. Plasma IL-6 levels correlate
with clinical and ultrasound measures of arthritis in patients with
systemic lupus erythematosus. Lupus 2014; 23:46-56.
16. Pelletier M, Maggi L, Micheletti A, Lazzeri E, Tamassia N,
Costantini C, et al. Evidence for a cross-talk between human neutrophils
and Th17 cells. Blood 2010; 115:335-43.
17. Bowness P, Ridley A, Shaw J, Chan AT, Wong-Baeza I, Fleming M, et
al. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers
are increased in ankylosing spondylitis. J Immunol 2011; 186:2672-80.
18. Robert M, Miossec P. Interleukin-17 and lupus: enough to be a
target? For which patients? Lupus 2020; 29:6-14.
19. Zickert A, Amoudruz P, Sundstrom Y, Ronnelid J, Malmstrom V,
Gunnarsson I. IL-17 and IL-23 in lupus nephritis - association to
histopathology and response to treatment. BMC Immunol 2015; 16:7.
20. Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmstrom V.
CD25brightCD4+ regulatory T cells are enriched in inflamed joints of
patients with chronic rheumatic disease. Arthritis Res Ther 2004;
6:R335-46.
21. Bommarito D, Hall C, Taams LS, Corrigall VM. Inflammatory cytokines
compromise programmed cell death-1 (PD-1)-mediated T cell suppression in
inflammatory arthritis through up-regulation of soluble PD-1. Clin Exp
Immunol 2017; 188:455-66.
22. Rao DA, Gurish MF, Marshall JL, Slowikowski K, Fonseka CY, Liu Y, et
al. Pathologically expanded peripheral T helper cell subset drives B
cells in rheumatoid arthritis. Nature 2017; 542:110-4.
23. Bocharnikov AV, Keegan J, Wacleche VS, Cao Y, Fonseka CY, Wang G, et
al. PD-1hiCXCR5- T peripheral helper cells promote B cell responses in
lupus via MAF and IL-21. JCI Insight 2019; 4.
24. Burkett PR, Meyer zu Horste G, Kuchroo VK. Pouring fuel on the fire:
Th17 cells, the environment, and autoimmunity. J Clin Invest 2015;
125:2211-9.
25. Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, et al. Th17 and natural
Treg cell population dynamics in systemic lupus erythematosus. Arthritis
Rheum 2009; 60:1472-83.
26. Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops
H, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis
Rheum 2010; 62:2876-85.
27. Menon B, Gullick NJ, Walter GJ, Rajasekhar M, Garrood T, Evans HG,
et al. Interleukin-17+CD8+ T cells are enriched in the joints of
patients with psoriatic arthritis and correlate with disease activity
and joint damage progression. Arthritis Rheumatol 2014; 66:1272-81.
28. Chemin K, Ramskold D, Diaz-Gallo LM, Herrath J, Houtman M, Tandre K,
et al. EOMES-positive CD4(+) T cells are increased in PTPN22 (1858T)
risk allele carriers. Eur J Immunol 2018; 48:655-69.